Evidence map›Paper›PMID 31263526›Full record

ArticleAddiction & health2018

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men.

Hassan Ziaaddini, Shima Heshmati, Maryam Chegeni, Mahboobeh Mousavi-Ramezanzade, Shahrzad Mazhari

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Addiction & health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hassan ZiaaddiniProfessor, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Shima HeshmatiPsychiatrist, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Maryam ChegeniPhD Student, HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran.
Mahboobeh Mousavi-RamezanzadeDepartment of Biostatistics and Epidemiology, School of Public Health, Kerman University of Medical Sciences, Kerman, Iran.
Shahrzad MazhariAssociate Professor, Neuroscience Research Center, Neuropharmacology Institute AND Department of Psychiatry, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Kerman University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBuprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of Iranian male opioid-dependent patients.

methodsA double-blind trial was carried out on a group of male opioid dependent patients in a psychiatric hospital in Kerman, Iran, during year 2017. A group of 100 men who met the diagnostic criteria for opiate dependence were included in the study from individuals who had referred for detoxification. They were allocated to the two groups receiving either buprenorphine (n = 51) or buprenorphine/naloxone (n = 49). Severity of withdrawal symptoms and signs were evaluated by Clinical Opiate Withdrawal Scale (COWS) and Adjective Rating Scale for Withdrawal (ARSW).

findingsThe mean scores of COWS and ARSW in the two groups treated with buprenorphine and buprenorphine/naloxone significantly reduced from the first day to the fifth day of detoxification (P < 0.050). Moreover, there was no significant difference between the two groups in terms of objective and subjective symptom reduction (P > 0.050).

conclusionBuprenorphine/naloxone is as effective as buprenorphine in controlling opiate withdrawal symptoms.

Indexed as

AddictionBuprenorphineBuprenorphine/naloxoneDetoxification

Identifiers

PMID31263526
PMCPMC6593171
OpenAlexW2958011020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.